ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 794,19
0,46%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Merrimack Pharmaceuticals Inc (MACK)

  7. Merrimack Pharmaceuticals Inc (MACK) Actualités

MACK

Merrimack Pharmaceuticals (MACK)

Merrimack Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MACK
DateHeureSourceTitreSymboleSociété
20/05/202422h05Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:MACKMerrimack Pharmaceuticals Inc
10/05/202422h45Edgar (US Regulatory)Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
10/05/202422h43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MACKMerrimack Pharmaceuticals Inc
10/05/202422h30Business WireMerrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common StockNASDAQ:MACKMerrimack Pharmaceuticals Inc
09/05/202413h45Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MACKMerrimack Pharmaceuticals Inc
09/05/202413h30Business WireMerrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of DissolutionNASDAQ:MACKMerrimack Pharmaceuticals Inc
30/04/202423h15Business WireMerrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of DissolutionNASDAQ:MACKMerrimack Pharmaceuticals Inc
27/03/202421h30Business WireMerrimack Receives $225 Million Milestone Payment from IpsenNASDAQ:MACKMerrimack Pharmaceuticals Inc
07/03/202422h42Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:MACKMerrimack Pharmaceuticals Inc
07/03/202422h30Business WireMerrimack Reports Full Year 2023 Financial ResultsNASDAQ:MACKMerrimack Pharmaceuticals Inc
07/03/202422h15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MACKMerrimack Pharmaceuticals Inc
07/03/202418h29Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
05/03/202422h44Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:MACKMerrimack Pharmaceuticals Inc
22/02/202422h46Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MACKMerrimack Pharmaceuticals Inc
13/02/202422h18Business WireMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)NASDAQ:MACKMerrimack Pharmaceuticals Inc
31/01/202420h08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MACKMerrimack Pharmaceuticals Inc
25/01/202422h05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
28/12/202322h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
02/11/202321h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MACKMerrimack Pharmaceuticals Inc
02/11/202321h30Business WireMerrimack Reports Third Quarter 2023 Financial ResultsNASDAQ:MACKMerrimack Pharmaceuticals Inc
03/08/202322h30Business WireMerrimack Reports Second Quarter 2023 Financial ResultsNASDAQ:MACKMerrimack Pharmaceuticals Inc
08/06/202322h16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MACKMerrimack Pharmaceuticals Inc
04/05/202323h27Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MACKMerrimack Pharmaceuticals Inc
04/05/202323h00Business Wire Merrimack Reports First Quarter 2023 Financial ResultsNASDAQ:MACKMerrimack Pharmaceuticals Inc
04/05/202322h35Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:MACKMerrimack Pharmaceuticals Inc
21/04/202322h16Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:MACKMerrimack Pharmaceuticals Inc
21/04/202315h22Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:MACKMerrimack Pharmaceuticals Inc
07/04/202315h17Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:MACKMerrimack Pharmaceuticals Inc
09/03/202322h40Business WireMerrimack Reports Full Year 2022 Financial ResultsNASDAQ:MACKMerrimack Pharmaceuticals Inc
09/03/202322h32Edgar (US Regulatory)Annual Report (10-k)NASDAQ:MACKMerrimack Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MACK

Dernières Valeurs Consultées

COIN
BEZBTC
Bezop
USOTC
GRSO
Grow Solutions (CE)
LSE
BR12
Lloyds Bcm 26
TSXV
GCCC.H
GCC Global Capital
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés